Bio-Rad Laboratories, Inc. $BIO Stock Sold by First Eagle Investment Management LLC

Bio-Rad Laboratories logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • First Eagle Investment Management cut its Bio-Rad stake by 52.9% in the third quarter, selling 2,756,858 shares; it still held 2,455,580 shares, worth about $927.5 million.
  • Bio-Rad reported quarterly EPS of $2.65, beating the $2.23 consensus estimate, while revenue of $656.4 million also topped expectations.
  • Analysts’ consensus rating was Hold, with an average price target of $366.67; company insiders sold 3,221 shares worth about $1.25 million over the past 90 days.
  • MarketBeat previews the top five stocks to own by December 1st.

First Eagle Investment Management LLC reduced its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 52.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,455,580 shares of the medical research company's stock after selling 2,756,858 shares during the period. Bio-Rad Laboratories makes up 1.4% of First Eagle Investment Management LLC's portfolio, making the stock its 25th largest holding. First Eagle Investment Management LLC owned approximately 9.18% of Bio-Rad Laboratories worth $927,497,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of BIO. Integrated Wealth Concepts LLC bought a new position in shares of Bio-Rad Laboratories during the 2nd quarter valued at about $27,000. Hollencrest Capital Management bought a new stake in shares of Bio-Rad Laboratories in the first quarter worth about $28,000. Root Financial Partners LLC bought a new stake in shares of Bio-Rad Laboratories in the third quarter worth about $34,000. Nykredit A S bought a new stake in shares of Bio-Rad Laboratories in the second quarter worth about $118,000. Finally, Signaturefd LLC increased its holdings in shares of Bio-Rad Laboratories by 51.7% in the third quarter. Signaturefd LLC now owns 437 shares of the medical research company's stock worth $165,000 after purchasing an additional 149 shares during the last quarter. Hedge funds and other institutional investors own 65.24% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Citigroup boosted their target price on Bio-Rad Laboratories from $300.00 to $330.00 and gave the stock a "hold" rating in a research report on Wednesday, August 5th. Royal Bank Of Canada raised their price target on Bio-Rad Laboratories from $390.00 to $440.00 and gave the company an "outperform" rating in a report on Thursday, November 5th. Wells Fargo & Company lifted their price objective on Bio-Rad Laboratories from $310.00 to $330.00 and gave the stock an "equal weight" rating in a research note on Wednesday, August 5th. Zacks Research raised Bio-Rad Laboratories from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 11th. Finally, Weiss Ratings raised Bio-Rad Laboratories from a "hold (c)" rating to a "hold (c+)" rating in a report on Monday, November 9th. One analyst has rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $366.67.

Check Out Our Latest Report on BIO

Insider Buying and Selling at Bio-Rad Laboratories

In other news, EVP James Barry sold 1,400 shares of the firm's stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $385.63, for a total value of $539,882.00. Following the completion of the sale, the executive vice president directly owned 625 shares of the company's stock, valued at $241,018.75. This trade represents a 69.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Courtney C. Enloe sold 902 shares of Bio-Rad Laboratories stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $386.17, for a total value of $348,325.34. Following the completion of the transaction, the executive vice president owned 750 shares of the company's stock, valued at approximately $289,627.50. This trade represents a 54.60% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,221 shares of company stock worth $1,247,049 over the last ninety days. Company insiders own 30.34% of the company's stock.

Bio-Rad Laboratories Stock Performance

Shares of NYSE:BIO opened at $358.91 on Wednesday. The firm has a fifty day simple moving average of $372.07 and a two-hundred day simple moving average of $318.08. Bio-Rad Laboratories, Inc. has a 52 week low of $236.73 and a 52 week high of $396.23. The company has a quick ratio of 2.37, a current ratio of 3.18 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $9.65 billion, a P/E ratio of 9.45 and a beta of 1.06.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its earnings results on Wednesday, November 4th. The medical research company reported $2.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.23 by $0.42. The firm had revenue of $656.40 million for the quarter, compared to analysts' expectations of $649.94 million. Bio-Rad Laboratories had a net margin of 39.45% and a return on equity of 3.58%. The business's revenue was up .5% compared to the same quarter last year. During the same period in the prior year, the company earned $2.26 EPS. On average, analysts expect that Bio-Rad Laboratories, Inc. will post 9.71 earnings per share for the current fiscal year.

Bio-Rad Laboratories Company Profile

(Free Report)

Bio-Rad Laboratories, Inc. develops, manufactures, and markets products used in life science research and clinical diagnostics. Founded in 1952 by David and Alice Schwartz, the company is headquartered in Hercules, California, and serves customers around the world. Through its Life Science segment, Bio-Rad supplies instruments, reagents, and software for areas including cell biology, genomics, protein analysis, and drug discovery. Its products support research at academic institutions, biotechnology and pharmaceutical companies, and other laboratories.

See Also

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Bio-Rad Laboratories Right Now?

Before you consider Bio-Rad Laboratories, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list.

While Bio-Rad Laboratories currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines